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In breast cancers, clinical symptoms of inflammation localised around the tumour at the time of diagnosis have been considered to
have poor prognosis significance. In this study, the biological mechanisms responsible for the deleterious action of monocytes in
cancer were investigated. The incubation of the breast-cancer-derived MDA-MB231 cells with monocytes resulted in an increase in
factors involved in cell invasion (i.e. both cancer cells and monocytes-associated urokinase and Tissue Factor, and PAI-1 and MMP-9
secretion). Moreover, the functions of monocytes were also modified. Incubation of monocytes with MDA-MB231 cancer cells
resulted in a downregulation in the secretion of the antiproliferative cytokine Oncostatin M, while the apoptotic factor TNF alpha was
dramatically increased. However, MDA-MB231 cancer cells have been shown to be resistant towards the apoptotic action of TNF
alpha. These findings demonstrate that incubation of MDA-MB231 cancer cells with monocytes induced a crosstalk, which resulted in
an increased expression of factors involved in cancer cell invasiveness and in a modification of monocytes function against cancer cells,
while inflammatory effects were increased.
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The importance of stroma in cancer formation, growth and
dissemination is now well established. In order to generate an
invasive tumour, cancer cells need several mutations, but also
formally necessitate sustenance from noncancer stroma cells,
which supply and permit cancer cell growth and invasion. The
presence of cytokines and inflammatory cells in cancer stroma,
indicating defence reaction against cancer, generally correspond to
a poor prognosis (Kleer et al, 2000). Furthermore, in breast cancer,
initial presentation with clinical symptoms of inflammation
indicates a particular aggressiveness and a worst prognosis than
other breast cancers (Chevallier, 1993; Palangie et al, 1994; Kleer
et al, 2000). However, the mechanisms leading to the pathological
action of stroma-localised inflammatory cells in cancer, such as
monocytes, remain poorly understood.
The current study was undertaken to explore whether the factors
of aggressiveness expressed by cancer cells were modified in the
presence of monocytes. We also analysed the consequences of the
incubation of monocytes with MDA-MB231 cancer cells on
functions of monocytes both in the defence against tumour cells
and in inflammatory functions. For this purpose, we tested the
consequences of the interaction of the highly invasive breast-
derived MDA-MB231 cancer cells with monocytes with an in vitro
system.
MATERIAL AND METHODS
Monocytes isolation
A measure of 80mm of blood from healthy volunteers was
collected in sterile polypropylene tubes (Costar, Cambridge, MA,
USA) containing 7.5ml of ACD (38mM citric acid, 74mM citrate
and 136mM glucose). Platelet-rich plasma was removed by
centrifugation (10min, 100g at room temperature). Mononuclear
cells were collected after centrifugation (45min, 400g at room
temperature) in Leucosep tubes (Costar, Cambridge, MA, USA)
containing 15ml of Ficoll (Diatrizoate-Ficoll d¼1.077, Eurobio,
Les Ullis, France). Mononuclear cells were then washed twice with
RPMI (RPMI 1640, Gibco, New York, NY, USA). These cells were
then resuspended and incubated in 10ml of RPMI with 10% foetal
calf serum (FCS) (Gibco, New York, NY, USA) 1% glutamine,
100Uml
 1 penicillin (Sarbach, Suresnes, France) and 100mgml
 1
streptomycin (Diamant, Puteaux, France) in 75ml flasks for 45min
(5% CO2, 95% water-saturated air mixture at 371C). Nonadherent
cells were removed. Adherent cells (approximately 90% mono-
cytes) were then washed twice with RPMI, scrapped, washed and
adjusted at 10
6ml
 1 in RPMI with 10% FCS, 1% glutamine,
100Uml
 1 penicillin and 100mgml
 1 streptomycin.
Cell culture
MDA-MB231 cancer cells were cultured in RPMI containing 10%
FCS, 1% glutamine, 100Uml
 1 penicillin and 100mgml
 1 strepto-
mycin.
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MDA-MB231 cancer cells were plated in 24-well plates (10
6 cells by
well) for 24h, to achieve 80% confluence in the wells. Then
0.5 10
6 monocytes were added into the wells and incubated for
24h at 371C. Controls consisted of monocytes and MDA-MB231
cancer cells alone.
After incubation, the supernatants were collected for cytokine
measurements and cells were collected for evaluation of mem-
brane-associated tissue factor (TF), urokinase (u-PA) and u-PAR
by flow cytometry.
Zymography assays for metalloproteinases (MMPs) and
u-PA secretions in supernatants
Supernatants of MDA-MB231 cancer cells cultured for 18 and 48h,
in the absence or presence of monocytes as indicated above, were
tested for MMP and u-PA by zymography.
For MMP assessment, supernatants were electrophorised on
7.5% polyacrylamide gel containing 10% SDS and gelatine
(1mgml
 1) under nonreducing conditions. After electrophoresis,
SDS was removed from the gels by washing for 1h in 2.5% triton
X-100 at room temperature. Gelatinase activity was revealed
overnight at 371C in a buffer containing 50mM Tris-HCl and 5mM
calcium chloride. The gels were stained with 0.25% Commassie
blue R250 (Sigma, Saint Quentin Fallavier, France) and gelatinase
activity was observed as clear bands against the blue background
of stained gelatine. Molecular weights were determined using
prestained standards.
For u-PA secretion, zymography was performed according to
Granelli-Piperno and Reich (1978).
Flow cytometry analysis of u-PA, u-PAR and TF expression
on MDA-MB231 cancer cells and monocyte membranes
A phycoerythrin-conjugated (PE) antibody against CD14
(Imunotech, Marseille, France) recognising monocytes cells by
direct immunofluorescence was used to make the distinction
between cancer cells and monocytes. The cell-membrane-asso-
ciated u-PA and -TF were determined by indirect immunofluor-
escence using first a murine monoclonal antibody against human
u-PA b-chain (American diagnostica, Greenwich, CT, USA) or
against TF (Serbio, Genevilliers, France) and secondly a fluorescein
isothiocyanate (FITC)-conjugated anti-mouse IgG (Immunotech,
Marseille, France). The cell-membrane-associated u-PAR was
determined by direct immunofluorescence using phycoerythrin-
conjugated antibody against CD87 (Pharmingen, San Diego, CA,
USA).
After incubation of MDA-MB231 cancer cells with monocytes, as
described above, cells were detached using nonenzymatic detach-
ment solution (Sigma, Saint Quentin Fallavier, France). Then
2 10
6 cells were resuspended and washed twice in phosphate
buffered saline (PBS). The first antibody (100mla t1 0mgml
 1) was
added to the cells and after a 15-min incubation period (41C), cells
were washed twice with 2ml of PBS. The second antibody (FITC-
labelled anti- mouse antibodies) was then added (100mla t
10mgml
 1) and cells were further incubated 15min at 41C. After
washing and centrifugation, the PE-labelled antibody against CD14
was added and the last incubation was performed for 15min at
41C. Cells were then washed, centrifuged and resuspended in 1ml
of PBS. Flow cytometry was performed with cytometer EPICS XL-
MCL (Coulter, USA) and the mean of fluorescence was measured.
On the FS Log vs SS Log cytogram, two regions were created
corresponding to monocytes and MDA-MB231 cancer cells.
Fluorescence histograms were associated with these two regions.
For each experiment, the purity of the populations defined on the
FS Log vs SS Log was analysed by labelling monocytes with a FITC-
conjugated antibody against CD14. Less than 5% of cells in MDA-
MB231 cancer cell region were positive for CD14, while more than
95% were positive in the monocyte region.
PAI-1, Oncostatin M and TNF alpha in supernatants
PAI-1, OSM and TNF alpha concentrations were determined in the
supernatants of incubation of monocytes with MDA-MB231 cancer
cells and in the control supernatants (monocytes and MDA-MB231
cancer cells alone).
The assays were performed by ELISA assays using Quantikine
Oncostatin (R&D systems, Abington, UK), Quantikine Elisa TNF
alpha kit (R&D systems, Abington, UK) and PAI-1 (Asserachrom
PAI-1, Diagnostic Stago, Asnie `res, France).
Assessment of TNF alpha-induced apoptosis
on MDA-MB231 cancer cells
Assessment was performed by an analysis of cell cycle distribution
on MDA-MB231 cancer cells whether or not treated by TNF alpha
at 50ngml
 1 for 72h. The Vindelov technique was used (Vindelov
and Christensen, 1990). Briefly, cells were harvested by gentle
scraping, pelleted by centrifugation and resuspended in 70mlo f
citrate buffer (250mM sucrose, 40mM trisodium citrate, 5% DMSO,
pH 7.6). Then, cells were treated with 350ml of trypsin (30mgml
 1)
(Sigma, Saint Quentin Fallavier, France) for 10min at room
temperature followed by treatment with 300ml of trypsin inhibitor
(0.5mgml
 1) (Sigma, Saint Quentin Fallavier, France) and Rnase
A (0.1mgml
 1). Nuclei were stained with 300ml of ice-cold
staining solution (0.4mgml
 1 propidium iodide (Sigma, Saint
Quentin Fallavier, France), 1.16mgml
 1 spermin and analysed by
flow cytometry. All solutions were prepared in a stock solution
containing 3.4mM trisodium citrate, 0.1% (vv
 1) Nonidet P-40,
1.5mM spermine, 0.5mM tribase, pH 7.6. The pre-G1 peak
corresponded to apoptotic cells.
RESULTS
Effects of incubation of MDA-MB231 cancer cells with
monocytes on MMPs secretion
As shown in Figure 1, the incubation of MDA-MB231 cancer cells
with monocytes induced a strong increase in the band of molecular
weight corresponding to MMP-9, which was demonstrated at both
18 and 48h of incubation.
Effects of incubation of MDA-MB231 cancer cells with
monocytes on membrane expression of invasiveness
factors: u-PAR/u-PA system and TF and on u-PA secreted
in the conditioned medium
Membrane expression of u-PA was spontaneously high on
MDA-MB231 cancer cells incubated alone and was low on
18 h 48 h
ABC A BC
Figure 1 Effect of 18- and 48-h incubation of MDA-MB231 with
monocytes on MMP-9 section: zymography study. (A) MDA-MB231 alone,
(B) monocytes alone, (C) MDA-MB231 incubated with monocytes.
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cancer cells with monocytes, the u-PA associated with the cell
membrane increased in both monocytes and MDA-MB231 cancer
cells, as shown in Figure 2. However, the incubation of monocytes
with MDA-MB231 cancer cells did not modify membrane-
associated u-PAR expression either on MDA-MB231 cancer cells
or on monocytes (Figure 2). In the conditioned medium, the
secretion of u-PA analysed by zymography was not modified when
MDA-MB 231 cells were incubated for 48h with monocytes
(Figure 3).
The TF expressed on membrane was spontaneously high on
MDA-MB231 cancer cells. Furthermore, it increased on both MDA-
MB231 cancer cells and monocytes after incubating these cells
together (Figure 4).
Effects of incubation of MDA-MB231 cancer cells and
monocytes on OSM, TNF alpha and PAI-1 secretion
in supernatants
OSM and TNF alpha were not found in the supernatants of MDA-
MB231 cancer cells cultured alone.
The incubation of MDA-MB231 cancer cells with monocytes was
responsible for a decreased secretion (61%) of OSM when
compared with secretion of monocytes incubated alone.
Also, the incubation of MDA-MB231 cancer cells with mono-
cytes resulted in a dramatic increase in TNF alpha in supernatants
(18000%) as compared with secretion by monocytes incubated
alone.
Incubation of MDA-MB231 cancer cells with monocytes induced
a mild increase in PAI-1 secretion (135% in comparison to the sum
of PAI-1 secreted by MDA-MB231 alone + that secreted by
monocytes alone).
These results are shown in Table 1.
TNF alpha-induced apoptosis on MDA-MB231 cancer cells
MDA-MB231 cancer cells were very poorly sensitive to TNF alpha
(Table 2). When MDA-MB231 cancer cells were incubated with
50ngml
 1 TNF alpha, less than 25% of cancer cells entered
apoptosis (pre-G1 phase) only after a 72-h incubation (Table 2).
DISCUSSION
The role of immune response in cancer progression seems to be
possibly dual and remains not well elucidated (Chambers et al,
1997; Jonjic et al, 1998; Koukourakis et al, 1998; Toi et al, 1999;
Shimura et al, 2000). Indeed, despite the role of monocytes/
macrophages in host defence, previous studies have suggested a
potential deleterious effect of stroma-localised monocytes/macro-
phage, in relation with enhanced angiogenesis (Etoh et al, 2000;
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Figure 2 Effect of incubation of MDA-MB231 with monocytes on u-PA and u-PAR expression on each cell type. The u-PA and u-PAR expression was
calculated as the percentage of fluorescence as compared with MDA-MB231 and monocytes alone (n¼4): (A) measurement of u-PA associated to MDA-
MB231 cancer cells, (B) measurement of u-PA associated to monocytes, (C) measurement of u-PAR associated to MDA-MB231 cancer cells, (D)
measurement of u-PAR associated to monocytes.
       A B         C     D
Figure 3 Effect of 48-h incubation of MDA-MB231 with monocytes on
u-PA secretion in the conditioned medium. The conditioned medium was
submitted to zymography in comparison with purified u-PA: (A) purified u-
PA, (B) supernatant of MDA-MB231 alone, (C) supernatant of MDA-
MB231 incubated with monocytes, (D) supernatant of monocytes alone.
Urokinase is visualised as a transparent lysis area of the gel after 36h. Two
lysis areas were observed with purified u-PA, one at 55kDa molecular
weight and a minor one corresponding to the low molecular weight u-PA
at 35kDa.
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yHashimoto et al, 2000; Ueno et al, 2000b). In the present study, we
investigated the consequences of the interaction between mono-
cytes and aggressive breast-derived MDA-MB231 cancer cells in
both the invasiveness capacities of cancer cells and the monocytes
functions.
Concerning the role of monocytes in cancer cell invasiveness
capacities, this cooperation was analysed on protease secretion
reported to be involved in cell migration, that is, u-PA and MMPs.
Indeed, evidence has accumulated that invasion and metastasis in
solid tumours require the action of tumour-associated proteases,
which promote the dissolution of the surrounding tumour matrix
and the basement membranes.
We showed that incubation of MDA-MB231 cancer cells with
monocytes induced an increased expression of membrane-
associated u-PA, on both monocytes and MDA-MB231 cancer
cells. It was not associated with modifications of cell-associated u-
PAR. In contrast with this increase in membrane-associated u-PA,
u-PA secreted in the conditioned medium was not modified when
MDA-MB231 cancer cells were incubated with monocytes. This
may be explained by the large excess of free u-PAR on cell
membrane which bind the secreted u-PA. Interestingly, the
increase in membrane-associated u-PA was not observed when
monocytes were incubated with the less aggressive breast-derived
MCF-7 cancer cells (results not shown).
This increase in u-PA associated to aggressive cancer cells could
contribute to the bad prognosis of inflammatory breast cancer.
Indeed, a high tumour expression of u-PA is associated with poor
prognosis in breast cancer. This is explained by an increased
invasiveness of cancer cells as membrane-associated u-PA is
involved in cancer cell invasion. Urokinase acts by degradation of
pericellular matrix, because of proteolytic cascade focused on cell
surface leading to plasmin generation and matrix metalloprotease
activation (Andreasen et al, 1997) but also by an increased cell
migration independent of proteolysis (Silvestri et al, 2002). In
addition, in relation to plasmin formation, uPA activates latent
growth factors and releases growth factors bound to extracellular
matrix (Odekon et al, 1994; Ribatti et al, 1999).
In parallel, it was shown that incubation of MDA-MB231 cancer
cells with monocytes increased PAI-1 secretion, which is also a
factor contributing to cancer cell invasiveness. Indeed, PAI-1 is a
major inhibitor of u-PA, even when associated to cell surface.
However, high expression of PAI-1 is paradoxically associated with
marked tumour spreading and poor prognosis (Pappot et al, 1995;
Andreasen et al, 1997; Schmitt et al, 1997; Look et al, 2002).
This pathogenic effect of PAI-1 in cancer aggressiveness was
confirmed by the report that cancer invasion and neovascularisa-
tion are abolished in PAI-1-deficient mice, and can be restored by
local induction of PAI-1 expression (Bajou et al, 1998). This
increase in PAI-1 allows a critical balance of u-PA associated to its
cell surface receptor, as it could represent a key molecule in the
rapid attachment/detachment events occurring at the cell leading
edge that are required for migration. (Lauffenburger and Horwitz,
1996).
Furthermore, incubation of monocytes with MDA-MB231 cancer
cells also induced an increase in u-PA associated to monocytes.
This increase could be critical for tumour invasion (Nielsen et al,
1996, 2001), as it has been shown that tumour xenografts grow
slowly in u-PA  /  mice (Frandsen et al, 2001). The mechanism of
u-PA increase on monocytes could be because of a binding of u-PA
secreted by MDA-MB231, as it was observed that the amount of u-
PA in the conditioned medium of monocytes incubated with MDA-
MB231 was higher than that of monocytes alone. It also could be
related to an increased production of u-PA by monocytes,
secondary to the increased secretion of TNF alpha observed when
monocytes were incubated with MDA-MB231. Indeed, TNF alpha
stimulates the production of u-PA by monocytes (Gyetko et al,
1992).
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Figure 4 Effect of incubation of MDA-MB231 with monocytes on TF expression on each cell type. The TF expression was calculated as the percentage of
fluorescence as compared with MDA-MB231 and monocytes alone (n¼4): (A) measurement of u-PA associated to MDA-MB231 cancer cells, (B)
measurement of u-PA associated to monocytes.
Table 1 Effect of incubation of MDA-MB231 with monocytes on
cytokine secretion in supernatants
Monocytes
alone
MDA-MB231
alone
Incubation of
monocytes with
MDA-MB231
OSM 383736 0 233738
TNF alpha 34733 0 614071018
PAI-1 3672 10647245 14847378
n=4. MDA-MB 231 cells were cultured in a 24-well culture plate. When the
confluence reached 80%, 0.5 10
6 monocytes were added and incubated for 18h.
Controls were performed with MDA-MB 231 alone and monocytes alone. Then the
supernatants were collected and cytokines were determined. Results are shown in
pgml
 1 units.
Table 2 Effect of TNF alpha on the cell cycle and apoptosis in MDA-
MB231 cancer cells
72-h incubation of MDA-MB231 with
Phase of cell cycle TNF alpha Control medium
Pre-G1 24.5% 2.1%
G0/G1 47.1% 57%
S 22.7% 30%
G2/M 5.7% 10.9%
n=5. TNF alpha-induced apoptosis of MDA-MB231 cancer cells was studied after
incubation of cancer cells with TNF alpha at a concentration of 50ngml
 1. The pre-
G1 peak is characteristic of apoptotic cells.
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MDA-MB231 cancer cells induced an increase in MMP-9 secretion.
As for u-PA, an increased secretion of MMP-9 is proposed to be
involved in cancer invasion and metastasis. Indeed, an increase in
MMP-9 secretion has been shown to enhance the invasive
capacities of breast cancer cells (Johansson et al, 2000). Moreover,
MMP-9 was detected more frequently in malignant breast
carcinoma than in benign tumour (Rha et al, 1997; Hanemaaijer
et al, 2000). However, the role of MMP-9 is less clear than that of u-
PA, as overexpression of MMP-9 in human breast cancer was
reported to be a favourable indicator in node-negative patients
(Scorilas et al, 2001).
After testing incubation of monocytes with MDA-MB231 cancer
cells on protease secretion, the cooperation between MDA-MB231
cancer cells and monocytes was analysed on TF expression. The
incubation of MDA-MB231 cancer cells with monocytes also
induced an increase in cell-associated TF expression in both
monocytes and MDA-MB231 cancer cells. TF, an initiator of blood
coagulation cascade, is expressed in a wide variety of cancer cells
and it is an independent prognostic indicator for overall survival
in cancer patients (Ueno et al, 2000a). This increase in TF, because
of cooperation between cancer cells and monocytes, could
contribute to the deleterious effect of monocytes in cancer
progression, as it plays an important role in cancer cell
invasiveness. Tissue factor is also implicated in both hypercoagu-
lablility in cancer patients (Hu et al, 1994) and enhancement of the
metastatic potential of cancer cells, probably by induction of
angiogenesis (Amirkhosravi et al, 1998; Rickles et al, 2001). Our
result can be an explanation for the observation that TF expressed
on monocytes in tumours is particularly abundant in close
proximity of invasive tumour cells (Vrana et al, 1996).
Concerning the effect of MDA-MB231 cancer cells on monocytes
functions relevant for antitumour effect, it was shown that the
incubation of monocytes with MDA-MB231 cancer cells resulted in
a decrease in OSM secretion, a cytokine which reduces the growth
rate of breast cancer cells (Li et al, 2001). Therefore, this
cooperation induces a reduction of monocyte-dependent host-
defence function.
The effect of the incubation of monocytes with MDA-MB231
cancer cells was also tested on TNF alpha, a cytokine secreted by
monocytes (Walczak et al, 1999). We demonstrated that TNF alpha
secretion by monocytes was dramatically increased when incu-
bated with MDA-MB231 cancer cells. However, this increase could
not participate in host defence against tumour cells by inducing
apoptotic signals, as MDA-MB231 cells are resistant to TNF alpha.
Indeed, high concentrations of TNF alpha induced apoptosis for
less than 25% of MDA-MB231 cancer cells. This resistance is
explained by constitutive activation of NF-KB in MDA-MB231
cancer cells (Denoyelle et al, 2001), which prevents TNF alpha-
induced apoptosis (Karin and Lin, 2002). Moreover, a correlation
between TNF alpha plasma concentration and the severity of the
disease in clinical studies has been reported (Sheen-Chen et al,
1997). This explains that in cancer patients, instead of mediating
cancer cell apoptosis, TNF alpha may be responsible for
discomfort symptoms, such as cancer-related fatigue and weigh-
tloss (Kurzrock, 2001).
In conclusion, this report underlines the potential role of
stroma-localised monocytes in cancer progression. Our results
demonstrate the existence of a crosstalk between aggressive breast-
derived MDA-MB231 cancer cells and monocytes, which resulted
in both the increase in factors involved in cancer cell invasiveness
and the decrease in some antitumour effects of monocytes.
Moreover, the increase of TNF alpha secretion, instead of inducing
cancer cell apoptosis, could produce potential systemic deleterious
effects in patients. These findings may be useful to explain the
deleterious prognostic significance of stromal monocytes infiltra-
tion in cancer.
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